Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

Core Viewpoint - Scilex Holding Company has regained compliance with Nasdaq's minimum closing bid price requirement, maintaining a minimum closing bid price of $1.00 per share for at least ten consecutive trading days as of April 30, 2025 [1] Company Overview - Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [3][5] - The company targets high unmet needs and large market opportunities with non-opioid therapies to improve patient outcomes [3] Commercial Products - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved for neuropathic pain relief associated with postherpetic neuralgia [3] - ELYXYB®, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [3] - Gloperba®, the first liquid oral version of colchicine for the prophylaxis of painful gout flares in adults [3] Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA), a viscous gel formulation for epidural injections to treat lumbosacral radicular pain, which has completed a Phase 3 study and received Fast Track status from the FDA [4] - SP-103, a next-generation formulation of ZTlido for acute pain, which has recently completed a Phase 2 trial and also received Fast Track status from the FDA [4] - SP-104, a low-dose delayed-release naltrexone hydrochloride for fibromyalgia treatment [4]